Shots:
Kaigene has granted Celltrion exclusive global rights to develop & commercialize KG006 (excl. Greater China & Japan) & KG002
As per the deal, Kaigene will receive $8M upfront, & ~$736M in milestone payments, incl. $11M in near-term milestones through the initiation of P-I trials, along with net sales-based tiered royalties
KG006 is an FcRn…
